The aim of the medical devices developed by Defymed is to respond to the request of the diabetic patients by allowing a more physiological treatment of diabetes.
For ExOlin®, the first clinical trial will prove safety and early performance of the device. The objective is to obtain CE-mark after the achievement of a more important clinical trial in different European states.
ExOlin® is a therapeutic innovation allowing a response to many patients at a global level. To enable a large-scale commercialization of the device, Defymed wishes to transfer a business license to a big medtech.